AbClon Inc. (KOSDAQ:174900)

Market Cap	182.59B
Revenue (ttm)	2.34B
Net Income (ttm)	-16.30B
Shares Out	17.69M
EPS (ttm)	-975.00
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	161,757
Average Volume	214,577
Open	10,120
Previous Close	10,160
Day's Range	9,980 - 10,470
52-Week Range	6,810 - 19,910
Beta	0.90
RSI	56.15
Earnings Date	n/a

About AbClon

AbClon Inc. engages in the research and development of antibody drugs in South Korea and Sweden. The company’s products in pipeline include NEST platform technology products for breast and gastric cancers; AffiMab platform technology products for colon cancer and autoimmune diseases; and CAR-T platform technology products for hematologic and ovarian cancers. AbClon Inc. was founded in 2010 and is based in Seoul, South Korea.

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2010
• Country: South Korea
• Stock Exchange: KOSDAQ
• Ticker Symbol: 174900

Financial Performance

In 2024, AbClon's revenue was 2.34 billion, a decrease of -18.67% compared to the previous year's 2.88 billion. Losses were -16.30 billion, 26.3% more than in 2023.